Épidémiologie et traitement des infections par le VHC en Égypte

1. Vignier N, Esmat G, Sharkawy AE, Hassany M, Bonnard P, Delarocque-Astagneau E, Said M, Raafat R, El-Hoseiny M, Fontanet A, Mohamed MK, Vray M. Reproducibility of liver stiffness measurements in hepatitis C virus (HCV)-infected patients in Egypt. J Viral Hepat ; 18(7): e358-e365. Abstract
2. Schwarzinger M, Mohamed MK, Gad RR, Dewedar S, Fontanet A, Carrat F, Luchini S.Risk perception and priority setting for intervention among hepatitis C virus and environmental risks: a cross-sectional survey in the Cairo community. BMC Public Health. 2010 Dec 20;10:773. Abstract
3. Paez Jimenez A, Sharaf Eldin N, Rimlinger F, El-Daly M, El-Hariri H, El-Hoseiny M, Mohsen A, Mostafa A, Delarocque-Astagneau E, Abdel-Hamid M, Fontanet A, Mohamed MK, Thiers V. HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt. Gut. 2010 Nov;59(11):1554-60. Abstract
4. Mostafa A, Taylor SM, el-Daly M, el-Hoseiny M, Bakr I, Arafa N, Thiers V, Rimlinger F, Abdel-Hamid M, Fontanet A, Mohamed MK.Is the hepatitis C virus epidemic over in Egypt? Incidence and risk factors of new hepatitis C virus infections. Liver Int. 2010 Apr;30(4):560-6. Abstract
5. Mostafa A, Mohamed MK, Saeed M, Hasan A, Fontanet A, Godsland I, Coady E, Esmat G, El-Hoseiny M, Abdul-Hamid M, Hughes A, Chaturvedi N.Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut. 2010 Aug;59(8):1135-40. Abstract
6. Mansour H, Laird ME, Saleh R, Casrouge A, Eldin NS, El Kafrawy S, Hamdy M, Decalf J, Rosenberg BR, Fontanet A, Abdel-Hamid M, Mohamed MK, Albert ML, Rafik M.Circulating plasmacytoid dendritic cells in acutely infected patients with hepatitis C virus genotype 4 are normal in number and phenotype. J Infect Dis. 2010 Dec 1;202(11):1671-5. Abstract
7. Laouénan C, Plancoulaine S, Mohamed MK, Arafa N, Bakr I, Abdel-Hamid M, Rekacewicz C, Obach D, Fontanet A, Abel L. Evidence for a dominant major gene conferring predisposition to hepatitis C virus infection in endemic conditions. Hum Genet. 2009 Jul 23. Abstract.
8. Jimenez AP, Mohamed MK, Eldin NS, Seif HA, El Aidi S, Sultan Y, Elsaid N, Rekacewicz C, El-Hoseiny M, El-Daly M, Abdel-Hamid M, Fontanet A. Injection drug use is a risk factor for HCV infection in urban Egypt. PLoS One. 2009 Sep 28;4(9):e7193. Abstract.
9. El Makhzangy H, Esmat G, Said M, Elraziky M, Shouman S, Refai R, Rekacewicz C, Gad RR, Vignier N, Abdel-Hamid M, Zalata K, Bedossa P, Pol S, Fontanet A, Mohamed MK. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol. 2009 Sep;81(9):1576-83. Abstract.
10. Schwarzinger M, Dewedar S, Rekacewicz C, Abd Elaziz KM, Fontanet A, Carrat F, Mohamed MK. Chronic hepatitis C virus infection: does it really impact health-related quality of life? A study in rural Egypt. Hepatology. 2004;40:1434-41. Abstract.
11. El Gaafary M, Rekacewicz C, Abdel-Rahman AG, Allam MF, El Hosseiny M, Abdel Hamid M, Colombani F, Sultan Y, El-Aidy S, Fontanet A, Mohamed MK. Surveillance of acute hepatitis C in Cairo, Egypt. J Med Virol, 2005;76:520-5. Abstract.
12. Arafa N, El Hoseiny M, Rekacewicz C, Bakr I, El-Kafrawy S, El Daly M, Aoun S, Marzouk D, Mohamed MK, Fontanet A. Changing pattern of HCV spread in rural areas of Egypt. J Hepatol 2005;43:418-24. Abstract.
13. Bakr I, Rekacewicz C, El Hosseiny M, Ismail S, El Daly M, El-Kafrawy S, Esmat G, Abdel-Hamid M, Mohamed M, Fontanet A. Higher clearance of HCV infection in females compared to males. Gut 2006 Jan 24; [Epub ahead of print]. Abstract.
14. Mohamed MK, Bakr I, El-Hoseiny M, Arafa N, Hassan A, Ismail S, Anwar M, Attala M, Rekacewicz C, Zalata K, Abdel-Hamid M, Esmat G, Fontanet A. HCV-related morbidity in a rural community of Egypt.
J Med Virol. 2006 Sep;78(9):1185-9; Abstract.
15. Marzouk D, Sass J, Bakr I, El Hosseiny M, Abdel-Hamid M, Rekacewicz C, Chaturvedi N, Mohamed MK, Fontanet A. Metabolic and cardiovascular risk profiles and HCV infection in rural Egypt. Gut. 2006 Sep 6; Abstract.
16. Deuffic-Burban S, Mohamed MK, Larouzé B, Carrat F, Valleron AJ. Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. J Hepatol, 2006;44:455-61. Abstract.
17. Males S, Gad RR, Esmat G, Abobakr H, Anwar M, Rekacewicz C, El Hoseiny M, Zalata K, Abdel-Hamid M, Bedossa P, Pol S, Mohamed MK, Fontanet A. Serum alpha-fetoprotein (AFP) level predicts treatment outcome in chronic hepatitis C. Antivir Ther. 2007;12:797-803. Abstract.
18. Abdoul H, Mallet V, Pol S, Fontanet A. Serum alpha-fetoprotein predicts treatment in chronic hepatitis C patients regardless of HCV genotype. PLoS ONE. 2008 jun 11;3(6):e2391 Abstract.
19. Gad RR, Males S, El Makhzangy H, Shouman S, Hasan A, Attala M, El Hoseiny M, Zalata K, Abdel-Hamid M, Fontanet A, Mohamed MK, Esmat G. Predictors of sustained virological response in patients with genotype 4 chronic hepatitis C. Liver International 2008, Sep;28(8):1112-9. Abstract.
20. Plancoulaine S, Mohamed MK, Arafa N, Bakr I, Rekacewicz C, Trégouët DA, Obach D, El Daly M, Thiers V, Féray C, Abdel-Hamid M, Abel L, Fontanet A. Dissection of familial correlations in Hepatitis C Virus (HCV) seroprevalence suggests evidence for intrafamilial viral transmission and genetic predisposition to infection. Gut. 2008 Sep;57(9):1268-74.Abstract.
21. Sharaf Eldin N, Ismail S, Mansour H, Rekacewicz C, El-Houssinie M, El-Kafrawy S, El Aidi S, Abdel-Hamid M, Esmat G, Pol S, Fontanet A, Mohamed MK. Symptomatic acute hepatitis C in egypt: diagnosis, spontaneous viral clearance, and delayed treatment with 12 weeks of pegylated interferon alfa-2a. PLoS ONE. 2008;3(12):e4085. Epub 2008 Dec 30. Abstract.
22. Paez Jimenez A, Sharaf El-Din N, El-Hoseiny M, El-Daly M, Abdel-Hamid M, El Aidi S, Sultan Y, Elsaid N, Mohamed MK, Fontanet A. Community transmission of HBV in Egypt: results from a case-control study in Greater Cairo. International Journal of Epidemiology, accepted. Abstract.